U.S. Markets open in 4 hrs 3 mins

KemPharm, Inc. (KMPH)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
8.65-0.07 (-0.80%)
At close: 4:00PM EDT

8.65 0.00 (0.00%)
Pre-Market: 5:11AM EDT

KemPharm, Inc.

1180 Celebration Boulevard
Suite 103
Celebration, FL 34747
United States
321 939 3416
http://kempharm.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees22

Key Executives

NameTitlePayExercisedYear Born
Dr. Travis C. MickleCo-Founder, Chairman, Pres & CEO541.85kN/A1973
Mr. R. LaDuane Clifton CPACFO, Sec. & Treasurer355.09kN/A1972
Dr. Sven GuentherExec. VP of R&D397.85kN/A1972
Ms. Christal M. M. MickleCo-Founder and VP of Operations & Product Devel.N/AN/A1979
Mr. Timothy J. Sangiovanni CPAVP & Corp. ControllerN/AN/A1984
Dr. Andrew BarrettVP of Scientific AffairsN/AN/AN/A
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

KemPharm, Inc., a specialty pharmaceutical company, discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company utilizes its Ligand Activated Therapy technology to generate improved prodrug versions of FDA-approved drugs, as well as to generate prodrug versions of existing compounds that may have applications for new disease indications. Its prodrug product candidate pipeline is focused on the high need areas of attention deficit hyperactivity disorder, stimulant use disorder, and CNS rare diseases, including idiopathic hypersomnia. KemPharm's lead clinical development candidate for the treatment of stimulant use disorder, KP879, is based on its prodrug of d-methylphenidate, known as serdexmethylphnidate. In addition, the company has received FDA approval for AZSTARYS, a new once-daily treatment for attention deficit hyperactivity disorder in patents age six years and older, and for APADAZ, an immediate-release combination product containing benzhydrocodone, a prodrug of hydrocodone, and acetaminophen. KemPharm, Inc. has collaboration and license agreement, with KVK-Tech, Inc. The company was incorporated in 2006 and is headquartered in Celebration, Florida.

Corporate Governance

KemPharm, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.